U.S. markets open in 6 hours 40 minutes
  • S&P Futures

    4,229.25
    +4.00 (+0.09%)
     
  • Dow Futures

    34,773.00
    +87.00 (+0.25%)
     
  • Nasdaq Futures

    13,681.75
    -28.00 (-0.20%)
     
  • Russell 2000 Futures

    2,271.40
    +3.50 (+0.15%)
     
  • Crude Oil

    65.41
    +0.51 (+0.79%)
     
  • Gold

    1,835.20
    +3.90 (+0.21%)
     
  • Silver

    27.83
    +0.35 (+1.28%)
     
  • EUR/USD

    1.2165
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.5770
    0.0000 (0.00%)
     
  • Vix

    16.69
    -1.70 (-9.24%)
     
  • GBP/USD

    1.4068
    +0.0079 (+0.56%)
     
  • USD/JPY

    108.9500
    +0.3680 (+0.34%)
     
  • BTC-USD

    58,861.94
    +404.67 (+0.69%)
     
  • CMC Crypto 200

    1,567.03
    +131.25 (+9.14%)
     
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • Nikkei 225

    29,518.34
    +160.52 (+0.55%)
     

Ovid Therapeutics Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., MBA, President and Chief Medical Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Virtual Global Healthcare Conference on Tuesday, May 19, at 1:20 p.m. ET.

A live audio webcast of the discussion can be accessed through the Events & Presentations section of the Company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website for two weeks following the live presentation.

About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). For more information on Ovid, please visit http://www.ovidrx.com/.

Contacts

Investors and Media:
Ovid Therapeutics Inc.
Investor Relations & Public Relations
irpr@ovidrx.com

Or

Investors:
Steve Klass
Burns McClellan, Inc.
sklass@burnsmc.com
(212) 213-0006

Media:
Katie Engleman
1AB
katie@1abmedia.com
(919) 333-7722